Australia and New Zealand PCR Systems Market Report and Forecast 2024-2032

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,699	120 Pages	Expert Market Research	February, 2024	EMAR18558314

Best Price Guarantee
Price	from $3,699
Length	120 Pages
Publisher	Expert Market Research
Published Date	February, 2024
SKU	EMAR18558314

Australia and New Zealand PCR Systems Market Report and Forecast 2024-2032

Australia and New Zealand PCR Systems Market Report and Forecast 2024-2032

Australia and New Zealand PCR Systems Market Outlook

The Australia and New Zealand PCR systems market size is anticipated to be driven by the increasing demand from Asia Pacific PCR systems market, which is likely to grow at a CAGR of 8.4% during the forecast period of 2024-2032. The market growth can be attributed to the rising emphasis on preventing pathogen associated infections and technical advancements in the medical research domain.

PCR Systems: Introduction

PCR systems are sophisticated laboratory equipment used to amplify tiny segments of DNA or RNA. By replicating a specific DNA sequence millions of times, these systems enable detailed analysis and study of genetic material. Essential in fields like molecular biology and medical diagnostics, PCR systems are pivotal for applications such as pathogen detection, genetic sequencing, and forensic analysis, playing a crucial role in disease diagnosis, research, and crime scene investigation.

Key Trends in the Australia and New Zealand PCR Systems Market

Continuous innovation, such as real-time PCR and digital PCR, offers higher accuracy, sensitivity, and throughput, meeting diverse research and diagnostic needs.

A shift towards miniaturized, portable PCR systems enabling rapid, on-site diagnostic testing, particularly useful in remote or resource-limited settings.

Increasing demand for customizable and automated PCR solutions to streamline workflows, reduce human error, and increase productivity in laboratories.

Development of systems capable of multiplexing to allow simultaneous detection of multiple targets in a single test, optimizing efficiency and cost-effectiveness.

Strong focus on complying with regulatory standards to ensure accuracy, reliability, and safety in diagnostic testing and research.

Incorporation of advanced data analysis and artificial intelligence to manage the large volumes of data generated, enhancing result interpretation and decision-making.

Australia and New Zealand PCR Systems Market Segmentation

Market breakup by Product

Reagents and Consumables
Instruments
Software and Services

Market breakup by Technique

Conventional PCR
Real-time PCR
Digital PCR
Reverse Transcription PCR
Hot-start PCR
Multiplex PCR
Other PCR Techniques

Market breakup by Application

Gene Expression Analysis
Genetic Sequencing
Genotyping
Nucleic Acid Detection
Nucleic Acid Synthesis
Standard Validation/Verification
Diagnostic Applications
Environmental Applications
Others

Market breakup by End User

Hospitals and Diagnostic Centres
Healthcare Industries
Academia and Government Organisations
Pharma-biotech Companies
Applied Industries
Other End Users

Market Breakup by Country

Australia
New Zealand

Australia and New Zealand PCR Systems Market Overview

In Australia, the PCR systems market is characterized by advanced healthcare research and a robust biotechnology sector. Significant investment in R&D activities, especially in healthcare and agricultural biotechnology, driving the demand for PCR systems. High focus on infectious disease control and genetic disorder management, leading to increased use of PCR in diagnostics and personalized medicine. Strong network of universities and research institutions adopting PCR systems for various scientific studies. Emphasis on high-quality standards and regulatory compliance in the biotechnology and healthcare sectors, influencing PCR system quality and usage.

In New Zealand, the PCR systems market is shaped by a commitment to high-quality healthcare and agricultural excellence. Usage of PCR systems in monitoring and controlling zoonotic and infectious diseases, crucial for both human healthcare and the significant agricultural sector. Investment in biotechnological research, with PCR systems playing a central role in genetic, medical, and agricultural research. Continuous development of healthcare infrastructure, promoting the adoption of advanced diagnostic methods, including PCR technologies. High standards for diagnostic and research tools, ensuring PCR systems meet the required precision and reliability for critical applications.

Australia and New Zealand PCR Systems Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.

Thermo Fisher Scientific Inc.
Roche Diagnostics (a division of F. Hoffmann-La Roche Ltd)
Bio-Rad Laboratories, Inc.
QIAGEN N.V.
Agilent Technologies, Inc.
Abbott Laboratories
Danaher Corporation
bioMérieux SA
PerkinElmer, Inc.
Fluidigm Corporation
Eppendorf AG
Promega Corporation
Analytik Jena AG (Endress+Hauser Group)
Illumina, Inc.
Becton, Dickinson and Company (BD)

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.

1 Preface: 1.1 Objectives of the Study; 1.2 Key Assumptions; 1.3 Report Coverage – Key Segmentation and Scope; 1.4 Research Methodology
2 Executive Summary
3 Australia and New Zealand PCR Systems Market Overview: 3.1 Australia and New Zealand PCR Systems Market Historical Value (2017-2023); 3.2 Australia and New Zealand PCR Systems Market Forecast Value (2024-2032)
4 Australia and New Zealand PCR Systems Market Dynamics: 4.1 Market Drivers and Constraints; 4.2 SWOT Analysis; 4.3 Porter’s Five Forces Model; 4.4 Key Demand Indicators; 4.5 Key Price Indicators; 4.6 Industry Events, Initiatives, and Trends; 4.7 Value Chain Analysis
5 Australia and New Zealand PCR Systems Market Segmentation: 5.1 Australia and New Zealand PCR Systems Market by Product; 5.1.1 Market Overview; 5.1.2 Reagents and Consumables; 5.1.3 Instruments; 5.1.4 Software and Services; 5.2 Australia and New Zealand PCR Systems Market by Technique; 5.2.1 Market Overview; 5.2.2 Conventional PCR; 5.2.3 Real-time PCR; 5.2.4 Digital PCR; 5.2.5 Reverse Transcription PCR; 5.2.6 Hot-start PCR; 5.2.7 Multiplex PCR; 5.2.8 Other PCR Techniques; 5.3 Australia and New Zealand PCR Systems Market by Application; 5.3.1 Market Overview; 5.3.2 Gene Expression Analysis; 5.3.3 Genetic Sequencing; 5.3.4 Genotyping; 5.3.5 Nucleic Acid Detection; 5.3.6 Nucleic Acid Synthesis; 5.3.7 Standard Validation/Verification; 5.3.8 Diagnostic Applications; 5.3.9 Environmental Applications; 5.3.10 Others; 5.4 Australia and New Zealand PCR Systems Market by End User; 5.4.1 Market Overview; 5.4.2 Hospitals and Diagnostic Centres; 5.4.3 Healthcare Industries; 5.4.4 Academia and Government Organisations; 5.4.5 Pharma-biotech Companies; 5.4.6 Applied Industries; 5.4.7 Other End Users; 5.5 Australia and New Zealand PCR Systems Market by Country; 5.5.1 Market Overview; 5.5.2 Australia; 5.5.3 New Zealand
6 Patent Analysis: 6.1 Analysis by Type of Patent; 6.2 Analysis by Publication Year; 6.3 Analysis by Issuing Authority; 6.4 Analysis by Patent Age; 6.5 Analysis by CPC Analysis; 6.6 Analysis by Patent Valuation; 6.7 Analysis by Key Players
7 Grants Analysis: 7.1 Analysis by Year; 7.2 Analysis by Amount Awarded; 7.3 Analysis by Issuing Authority; 7.4 Analysis by Grant Application; 7.5 Analysis by Funding Institute; 7.6 Analysis by NIH Departments; 7.7 Analysis by Recipient Organization
8 Funding Analysis: 8.1 Analysis by Funding Instances; 8.2 Analysis by Type of Funding; 8.3 Analysis by Funding Amount; 8.4 Analysis by Leading Players; 8.5 Analysis by Leading Investors; 8.6 Analysis by Geography
9 Partnership and Collaborations Analysis: 9.1 Analysis by Partnership Instances; 9.2 Analysis by Type of Partnership; 9.3 Analysis by Leading Players; 9.4 Analysis by Geography
10 Regulatory Framework: 10.1 Regulatory Overview
11 Supplier Landscape: 11.1 Thermo Fisher Scientific Inc.; 11.1.1 Financial Analysis; 11.1.2 Product Portfolio; 11.1.3 Demographic Reach and Achievements; 11.1.4 Mergers and Acquisitions; 11.1.5 Certifications; 11.2 Roche Diagnostics (a division of F. Hoffmann-La Roche Ltd); 11.2.1 Financial Analysis; 11.2.2 Product Portfolio; 11.2.3 Demographic Reach and Achievements; 11.2.4 Mergers and Acquisitions; 11.2.5 Certifications; 11.3 Bio-Rad Laboratories, Inc.; 11.3.1 Financial Analysis; 11.3.2 Product Portfolio; 11.3.3 Demographic Reach and Achievements; 11.3.4 Mergers and Acquisitions; 11.3.5 Certifications; 11.4 QIAGEN N.V.; 11.4.1 Financial Analysis; 11.4.2 Financial Portfolio; 11.4.3 Demographic Reach and Achievements; 11.4.4 Mergers and Acquisitions; 11.4.5 Certifications; 11.5 Agilent Technologies, Inc.; 11.5.1 Financial Analysis; 11.5.2 Product Portfolio; 11.5.3 Demographic Reach and Achievements; 11.5.4 Mergers and Acquisitions; 11.5.5 Certifications; 11.6 Abbott Laboratories; 11.6.1 Financial Analysis; 11.6.2 Product Portfolio; 11.6.3 Demographic Reach and Achievements; 11.6.4 Mergers and Acquisitions; 11.6.5 Certifications; 11.7 Danaher Corporation; 11.7.1 Financial Analysis; 11.7.2 Product Portfolio; 11.7.3 Demographic Reach and Achievements; 11.7.4 Mergers and Acquisitions; 11.7.5 Certifications; 11.8 bioMérieux SA; 11.8.1 Financial Analysis; 11.8.2 Product Portfolio; 11.8.3 Demographic Reach and Achievements; 11.8.4 Mergers and Acquisitions; 11.8.5 Certifications; 11.9 PerkinElmer, Inc.; 11.9.1 Financial Analysis; 11.9.2 Product Portfolio; 11.9.3 Demographic Reach and Achievements; 11.9.4 Mergers and Acquisitions; 11.9.5 Certifications; 11.10 Fluidigm Corporation; 11.10.1 Financial Analysis; 11.10.2 Product Portfolio; 11.10.3 Demographic Reach and Achievements; 11.10.4 Mergers and Acquisitions; 11.10.5 Certifications; 11.11 Eppendorf AG; 11.11.1 Financial Analysis; 11.11.2 Product Portfolio; 11.11.3 Demographic Reach and Achievements; 11.11.4 Mergers and Acquisitions; 11.11.5 Certifications; 11.12 Promega Corporation; 11.12.1 Financial Analysis; 11.12.2 Product Portfolio; 11.12.3 Demographic Reach and Achievements; 11.12.4 Mergers and Acquisitions; 11.12.5 Certifications; 11.13 Analytik Jena AG (Endress+Hauser Group); 11.13.1 Financial Analysis; 11.13.2 Product Portfolio; 11.13.3 Demographic Reach and Achievements; 11.13.4 Mergers and Acquisitions; 11.13.5 Certifications; 11.14 Illumina, Inc.; 11.14.1 Financial Analysis; 11.14.2 Product Portfolio; 11.14.3 Demographic Reach and Achievements; 11.14.4 Mergers and Acquisitions; 11.14.5 Certifications; 11.15 Becton, Dickinson and Company (BD); 11.15.1 Financial Analysis; 11.15.2 Product Portfolio; 11.15.3 Demographic Reach and Achievements; 11.15.4 Mergers and Acquisitions; 11.15.5 Certifications
12 Australia and New Zealand PCR Systems Market - Distribution Model (Additional Insight): 12.1 Overview; 12.2 Potential Distributors; 12.3 Key Parameters for Distribution Partner Assessment
13 Key Opinion Leaders (KOL) Insights (Additional Insight)
14 Company Competitiveness Analysis (Additional Insight): 14.1 Very Small Companies; 14.2 Small Companies; 14.3 Mid-Sized Companies; 14.4 Large Companies; 14.5 Very Large Companies
15 Payment Methods (Additional Insight): 15.1 Government Funded; 15.2 Private Insurance; 15.3 Out-of-Pocket; *Additional insights provided are customisable as per client requirements.